Celltech Group plc Announces Interim Report for the Six Months Ended 30 June 2003 Slough, UK, August 19, 2003 (PRIMEZONE) -- Celltech Group plc (LSE:CCH) (NYSE:CLL) Interim Report for the Six Months Ended 30 June 2003 As a leading European biotechnology company with a strong...

Celltech Group plc: US Food and Drug Administration Approves Zavesca -- First Oral Treatment Option for Type 1 Gaucher Disease SLOUGH, U.K., August 1, 2003 (PRIMEZONE) -- Celltech Group plc (LSE:CCH) (NYSE:CLL) and Actelion Ltd (SWX:ATLN) today announced that the US Food and Drug Administration (FDA) has approved Zavesca(R)...

Celltech Group plc: Celltech Announces Long-Term Microbial Manufacturing Agreement with Lonza SLOUGH, England, July 13, 2003 (PRIMEZONE) -- Celltech Group plc (NYSE:CLL) (LSE:CCH) announced today that it has entered into a long-term supply agreement with Lonza Biotec, a division of Lonza...